Mukhtar Ullah is currently a Doctoral Student at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) since January 2021. Prior experience includes serving as a Scientific Researcher at City University of Hong Kong from August 2017 to February 2019 and working as an M.Phil. Scholar at the Centre For Applied Molecular Biology (CAMB) from October 2015 to July 2017. Additionally, Mukhtar Ullah held the position of Research Assistant at the Molecular Virology Lab of CEMB from November 2015 to June 2016. Mukhtar Ullah’s educational background includes a Master’s Degree in Molecular Biology from the University of the Punjab, completed in August 2017, and a Bachelor of Science degree from Kohat University of Science & Technology, awarded in September 2015.
This person is not in any offices
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic researchers and clinicians work hand in hand to advance the understanding of vision, its diseases and to develop new therapies for vision loss. The institute is constituted as a foundation. IOB started operations in 2018. At IOB, we accelerate the conversion of basic research into innovative treatments which change the field of ophthalmic therapy. Interdisciplinary teams of researchers and clinicians work hand in hand. These problem-solvers and innovators have in-depth knowledge of unmet medical needs, and daily exposure to patients. Together, they improve the understanding of vision, and of the cells involved in eye disease. In this highly collaborative environment, IOB turns discoveries and technologies into clinical benefits for patients with blinding conditions. We help advance the practice of ophthalmic disease based on the genetic, structural and functional understanding of the cell types and their interactions within the human eye. At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic researchers and clinicians work hand in hand to advance the understanding of eye diseases and to develop new therapies for vision loss.